by The gene and cell therapies targeting CNS disorders market has been gaining significant traction over the recent past driven by the rising prevalence of various neurological disorders including Parkinson’s disease, Alzheimer’s disease, Cerebral Palsy, and Spinal Muscular Atrophy among others. Gene and cell therapies provide long term benefits to patients by reducing morbidity and safely improving the quality of life.
The Global gene and cell therapies targeting CNS disorders market is estimated to be valued at US$ 9.45 Mn in 2024 and is expected to exhibit a CAGR of 6.0% over the forecast period 2024 to 20301.
Key Takeaways
Key Players: Key players operating in the gene and Cell Therapies Targeting CNS Disorders Market include Byucksan, Great Lakes Textiles, ISOVER (Saint Gobain), Johns Manville, Knauf Insulation, National Industrial Co., NTN OOD, Owens Corning, PGF Insulation, Rockwool International AS, Kingspan Group, and Rosewool Insulation Refractory Co. Ltd. These players are focusing on new product launches and strategic collaborations to expand their market share.
Key Opportunities: Rising investments in R&D activities related to gene therapies represents a major growth opportunity for players in this market. Further, the development of novel and advanced cell-based therapies using neural stem cells, mesenchymal stem cells, and induced pluripotent stem cells to treat neurodegenerative diseases offers lucrative prospects.
Global Expansion: Major players are focusing on geographic expansion plans across North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. For instance, in August 2022, Great Lakes Textiles partnered with Rosewool Insulation Refractory Co. Ltd to distribute its cell therapy products in Europe and Asia Pacific. This will help the company to leverage the distribution network of its partner in high potential markets.
Market Drivers
Increasing research funding for CNS disorders: Growing funding from private and government bodies to support research related to rare and orphan neurological disorders is a key factor driving development of innovative gene and cell therapies. For instance, the National Institutes of Health provides more than US$ 3 billion annually for research in Parkinson’s disease and Alzheimer’s disease. Such funding helps clinical translation of emerging therapies.
Patient demand for effective treatments: Most CNS disorders have no cure and currently available treatment options only alleviate symptoms and improve quality of life. Patients are keen to adopt advanced therapies with potential to slow or halt the progression. This is significantly boosting the demand for gene and cell therapies targeting the root cause of neurological conditions.
PEST Analysis
Political: Governments around the world are promoting research and development activities related to gene and cell therapies targeting CNS disorders through funding and partnerships with industry players. Many countries have also simplified regulations to promote innovation in this sector.
Economic: The rising healthcare expenditure on treatment of chronic CNS disorders and growing geriatric population that is more prone to such conditions are driving the demand for new and effective therapies. Manufacturers are investing heavily in R&D to develop advanced therapies.
Social: Growing awareness about gene and cell therapies and their advantages over conventional treatment methods have increased social acceptance of such novel treatment approaches. Patients and caregivers are open to new options that can potentially provide better outcomes.
Technological: Significant advancements have been made in gene and cell therapy development technologies such as viral and non-viral gene delivery systems, gene editing tools, stem cell biology, and regenerative medicine. Companies are leveraging these technologies to create more targeted and efficient therapy candidates.
The North American region accounts for the largest share of the Gene And Cell Therapies Targeting CNS Disorders Market Demand in terms of value. This can be attributed to presence of major market players, higher healthcare spending, advanced research infrastructure and streamlined approval process for novel therapies in the United States.
The Asia Pacific region is anticipated to witness the fastest growth in the market during the forecast period. This is majorly due to rising geriatric population, increasing incidence of neurological disorders, growing healthcare expenditure, and improving economic conditions in many countries. Rising investments by international players to tap into the market potential in China and India will further support the regional market expansion.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it.
